Pfizer Inc. (PFE)
This $25 Billion Acquisition Just Unlocked a New Era of Growth for Pfizer — and Why It's a Flawless Safe-Haven for Retirees
Pfizer (NYSE:PFE | PFE Price Prediction) is in the middle of its biggest reinvention in a generation, leaning on the Seagen oncology platform and the freshly closed Metsera obesity assets to offset a COVID revenue cliff and looming patent losses.
A Sizzling 6.7% Dividend Yield? 1 Under-the-Radar Reason I Am Holding Off on Pfizer Stock at $25
At $25.60, Pfizer (NYSE:PFE | PFE Price Prediction) sits in Hold territory on Wall Street's consensus.
Prediction: Pfizer Stock Will Double on This Date
Pfizer (NYSE:PFE | PFE Price Prediction) trades at $25.62, pays a 6.7% dividend yield, and just posted five straight quarterly EPS beats before stumbling in Q1.
Amneal and Pfizer GLP-1 Deal: New Growth Lever?
AMRX is expanding into GLP-1 manufacturing and biosimilars, using partnerships and acquisitions to strengthen its higher-value product strategy.
PFE Gets FDA Nod for Expanded Use of Hemophilia Drug Hympavzi
Pfizer wins FDA approval to expand Hympavzi's use in additional hemophilia A and B patient groups, including children with inhibitors.
Pfizer Inc. (PFE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Pfizer Inc. (PFE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Wall Street Breakfast Podcast: Pfizer Chases Monthly Edge
Pfizer (PFE) reports positive mid-stage trial data for berobenatide, aiming to be the first GLP-1 obesity therapy with monthly dosing. PFE plans up to 10 Phase 3 trials for berobenatide, targeting long-term obesity management and related conditions.
US FDA approves Pfizer's bleeding disorder drug for children
The U.S. Food and Drug Administration has approved Pfizer's drug to prevent or reduce the frequency of bleeding episodes in children and in certain patients with hemophilia, the company said on Monday.
3 Dividend Stocks to Buy Hand Over Fist in June
Pfizer has a rich pipeline of drugs in development, at least some of which are likely to sell well. UPS has turned away from Amazon.com and toward more profitable deliveries.
Pfizer's monthly obesity shot has side-effect profile similar to Wegovy in midstage trial
Pfizer presented data on Saturday that showed a monthly dose of an experimental obesity drug it acquired through its purchase of Metsera last year had a similar side-effect profile as rival Novo Nordisk's weekly injection Wegovy.
Why Pfizer And Eli Lilly Are Betting On This $1.3 Billion AI Drug Discovery Startup
L
Pfizer vs Merck: Chasing High Yield vs Higher Returns
Pfizer (NYSE:PFE | PFE Price Prediction) and Merck (NYSE:MRK) both just closed earnings chapters that frame the 2026 dividend debate clearly.
